In Vivo Methylation Studies Of Mefv Gene by Karaca, Esra
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
İSTANBUL TECHNICAL UNIVERSITY ? INSTITUTE OF SCIENCE AND TECHNOLOGY 
 
M.Sc. Thesis  by 
Esra KARACA, B.Sc. 
521061208 
                Date of submission : 5 May 2008 
Date of defence examination : 11 June 2008 
Supervisor (Chairman): Assist. Prof. Dr. Eda TAHİR TURANLI 
Members of the Examining Committee: Assoc. Prof. Dr. Arzu KARABAY 
KORKMAZ 
Prof. Dr. Uğur ÖZBEK 
 
 
JUNE 2008 
 
IN VIVO METHYLATION STUDIES OF MEFV GENE 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
İSTANBUL TEKNİK ÜNİVERSİTESİ ? FEN BİLİMLERİ ENSTİTÜSÜ 
 
YÜKSEK LİSANS TEZİ 
Esra KARACA 
521061208 
                Teslim Tarihi : 5 Mayıs 2008 
Savuma Tarihi  : 11 Haziran 2008 
Tez Danışmanı : Yrd. Doç. Dr. Eda TAHİR TURANLI 
Diğer Jüri Üyeleri : Doç. Dr. Arzu KARABAY KORKMAZ 
  Prof. Dr. Uğur ÖZBEK 
 
HAZİRAN 2008 
 
MEFV GENİNİN İN VİVO METİLASYON 
ÇALIŞMALARI 
 
 iii 
 
ACKNOWLEDGEMENTS 
I would like to express my sincere gratitude to my advisor Assist. Prof. Dr. EDA 
TAHİR TURANLI for her guidence, patience, and continuous support to me 
throughout this study. I especially would like to thank her for giving me the 
opportunity to work independently during my studies. I am grateful to her for 
listening and criticizing my ideas, which helped me to gain a strong scientific point 
of view. She provided me all the opportunities required to complete my master 
thesis. It was a pleasure for me to work with her. 
I would like to thank to the Cerrahpaşa Group Dr. HASAN YAZICI, Dr. TANJU 
BEĞER, Dr. DENİZ ERDİNÇLER, Dr. ASLI ÇUNGURLU, Dr. MURAT 
BOLAYIRLI, and nurses GÜL ÖZKESKİN, and NEFİSE YURTSEVER for their 
kind help in providing blood samples. 
I also would like to thank to my lab partners in Human Genetics Group SİNEM 
KARAMAN, GÖKÇE ÇELİKYAPI, and SELÇUK DAŞDEMİR for their help and  
support in establishing the genotyping techniques we have used. It was a pleasant 
experience for me to work with them. 
I would like to thank to TUBİTAK for providing me financial support throughout my 
master study. I also want to thank to L’OREAL for financing this project, and 
Istanbul Technical University Molecular Biology Genetics and Biotechnology 
Research Center for providing a supportive working environment for me. 
I also would like to thank to my family for their continuous love and support. 
 
 
 
2008, Spring                                                                                Esra KARACA 
 iv 
 
TABLE OF CONTENTS 
ABBREVIATIONS vi 
LIST OF TABLES vii 
LIST OF FIGURES viii 
SUMMARY x 
ÖZET xii 
1. INTRODUCTION  
  1.1. Theoretical Background 1 
    1.1.1. FMF and MEFV gene 1 
      1.1.1.1. Familial mediterranean fever disease 1 
      1.1.1.2. The mediterranean fever gene, MEFV 1 
      1.1.1.3. Structure and function of pyrin, the protein product of MEFV gene 2 
      1.1.1.4. Common MEFV mutations and MEFV expression levels 5 
    1.1.2. DNA methylation and epigenetics 7 
      1.1.2.1. Epigenetic mechanisms in higher eukaryotes 7 
      1.1.2.2. Gene expression regulation via DNA methylation 9 
  1.2. Practical Background 10 
    1.2.1. SNP genotyping 10 
      1.2.1.1. Polymerase chain reaction 11 
      1.2.1.2. Restriciton enzyme digestion 11 
      1.2.1.3. Agarose gel electrophoresis 11 
    1.2.2. DNA methylation detection 12 
      1.2.2.1. Bisulfite treatment 12 
      1.2.2.2. Methylation specific PCR 12 
      1.2.2.3. Bisulfite sequencing 12 
  1.3. Aim of the Study 12 
2. MATERIALS AND METHODS 14 
  2.1. Materials and Laboratory Equipments 14 
    2.1.1. Equipments 14 
    2.1.2. Chemicals, Enzymes and Markers 14 
  2.2. CpG Island Analysis of MEFV Gene 14 
  2.3. DNA Isolation 14 
    2.3.1. Colection and storage conditions of blood samples 14 
    2.3.2. DNA isolation from whole blood 15 
    2.3.3. Spectrophotometric calculation of DNA concentrations 15 
    2.3.4. Preparation of working aliquots of genomic DNA 15 
 
 
 
 
 v 
 
  2.4. E148Q Genotyping 15 
    2.4.1. Polymerase chain reaction 15 
    2.4.2. Agarose gel electrophoresis for detection of PCR amplification 16 
    2.4.3. Restriction enzyme digestion of PCR products 17 
    2.4.4. Determination of restriction pattern by agarose gel electrophoresis 17 
    2.4.5. Determination of genotypes 18 
  2.5. DNA Methylation Analysis 18 
    2.5.1. Bisulfite treatment 18 
    2.5.2. Methylation specific PCR 20 
      2.5.2.1. Amplification of control DNA fragment from genomic DNA for     
preparation of Unmethylated MSP control 
21 
      2.5.2.2. Purification of PCR product 22 
      2.5.2.3. SssI methylation of control fragment for preparation of methylated 
MSP control 
23 
      2.5.2.4. Purification of methylated DNA fragment 23 
      2.5.2.5. Confirmation of methylation 23 
      2.5.2.6. Bisulfite treatment of control fragments 23 
      2.5.2.7. MSP Primer design 23 
      2.5.2.8. MSP PCR conditions 26 
    2.5.3. Bisulfite sequencing 26 
      2.5.3.1. BSS primer design 26 
      2.5.3.2. BSS PCR conditions 27 
      2.5.3.3. Sequence PCR 29 
      2.5.3.4. Purification of sequence PCR products 29 
      2.5.3.5. Sequence data analysis 30 
3. RESULTS 31 
  3.1. CpG Island Analysis Results 31 
  3.2. E148Q Genotyping Results 32 
  3.3. Methylation Specific PCR Results 34 
  3.4. Bisulfite Sequencing Results 36 
  3.5 DNA Methylation and MEFV Expression Analysis 37 
4. DISCUSSION 43 
5. CONCLUSION AND FURTHER COMMENTS 46 
REFERENCES 48 
APPENDIX A 53 
APPENDIX B 54 
APPENDIX C 57 
APPENDIX D 58 
APPENDIX E 76 
CURRICULUM VITAE 86 
  
 
 vi 
 
ABBREVIATIONS 
FMF : Familial Mediterranean Fever 
MEFV : Mediterranean Fever (gene) 
IL               : Interleukin 
PCR : Polymerase Chain Reaction 
DNA : Deoxyribonucleic Acid 
MSP           :Metylation Specific PCR 
BSS            :Bisulfite Sequencing 
M Primer  :Methylated, bisulfate treated DNA-specific primer 
U Primer   :Unmethylated, bisulfate treated DNA-specific primer
 
 
 
 
 vii 
 
LIST OF TABLES 
Table 2.1      : E148Q genotyping primers 16 
Table 2.2      : E148Q PCR mix 16 
Table 2.3      : Program of E148Q PCR 16 
Table 2.4       Restriction mix for AvaI digestion 17 
Table 2.5       Restriction fragments of E148Q alleles 17 
Table 2.6       Bisulfite reaction mix 19 
Table 2.7       Bisulfite reaction program 19 
Table 2.8       Primers used to amplify control DNA fragment 21 
Table 2.9       PCR mix used for amplification of MSP control fragment 22 
Table 2.10     PCR program used for amplification of MSP control fragment 22 
Table 2.11     SssI Methylation mix 23 
Table 2.12     MSP U primer sequences 24 
Table 2.13     MSP M primer sequences 25 
Table 2.13     MSP PCR mix 26 
Table 2.14     MSP PCR program 26 
Table 2.15     BSS Primer sequences 27 
Table 2.16     PCR mix of first round BSS PCR 28 
Table 2.17     PCR program of first round PCR 28 
Table 2.18     PCR mix of second round BSS PCR 28 
Table 2.19     PCR program of second round PCR 28 
Table 2.20     Sequence PCR mix 29 
Table 2.21     Sequence PCR program 29 
 
 viii 
 
LIST OF FIGURES 
Figure 1.1       : Domains of pyrin protein 3 
Figure 1.2       : Estimated model of pyrin action in IL-1beta mediated 
                          inflammation 
4 
Figure 1.3       : Proposed model of Pyrin B30.2 domain and Caspase-1  
                          interaction 
4 
Figure 1.4       : Cytosine methylation by DNA methyltransferases 8 
Figure 1.5       : Histone modifications and chromatin state 8 
Figure 2.1       : Illustration of CpG island software 14 
Figure 2.2       : Expected restriction patterns of E148Q genotypes 18 
Figure 2.3       : Control primer sites on mefv genomic sequence 21 
Figure 2.4       : Methylation Specific Primer areas selected by MethylPrimer  
                          Express  software 
24 
Figure 2.5       : MSP U primers on unmethylated, bisulfite treated MEFV  
                          genomic DNA 
25 
Figure 2.6       : MSP M primers on methylated, bisulfite treated MEFV  
                          genomic DNA 
26 
Figure 2.7       : Bisulfite Sequencing Primers 27 
Figure 3.1       : CpG island on the MEFV genomic DNA sequence 32 
Figure 3.2       : PCR-amplified 244bp DNA fragment including E148Q site. 33 
Figure 3.3       : AvaI restriction analysis of 6 samples 33 
Figure 3.4       : PCR amplified control DNA for MSP 34 
Figure 3.5       : BstUI digestion of methylated and unmethylated MSP  
                          control DNA fragment 
35 
Figure 3.6       : MSP results of methylated and unmethylated control DNA 
                          fragments 
35 
Figure 3.7       : Methylation Specific PCR results 8 DNA samples 36 
Figure 3.8       : Bisulfite sequencing PCR-amplified DNA fragments for 18  
                          DNA samples 
36 
Figure 3.9       : Forward primer-red BSS sequence 37 
Figure 3.10     : Reverse primer-red BSS sequence 37 
Figure 3.11     : Global methylation at the second exon of MEFV gene  
                          compared to MEFV gene expression levels. 
38 
Figure 3.12     : CpG methylation at E148Q site compared to MEFV gene  
                          expression 
38 
Figure 3.13     : Average CpG methylation for each CpG site throughout the 
                          second exon of MEFV gene 
39 
Figure 3.14     : Comparison of average DNA methylation between the first  
                           half and the second half of the second exon of MEFV gene. 
39 
Figure 3.15     : DNA Methylation comparison between wildtype and E148Q  
                           heterozygotes for each CpG site. 
 
40 
 ix 
 
Figure 3.16      : Comparison of average DNA methylation of second exon of 
                           MEFV gene and average MEFV expression between  
                           wildtype and E148Q heterozygote samples. 
40 
Figure 3.17       : Comparison of average DNA methylation of E148Q site  
                            and average MEFV expression between wildtype and  
                            E148Q heterozygote samples 
41 
Figure 3.18       : Average MEFV Expression vs Average Exon Methylation  
                            Comparison Between FMF Samples (N=9) and Healthy  
                            Controls (N=15) 
41 
Figure 3.17       : Average MEFV Expression vs Average CpG Methylation    
                           (at 9th, 10th and 11th Position) Comparison Between FMF  
                           Samples (N=9) and Healthy Controls (N=15) 
42 
 
 x 
 
In vivo Methylation Studies of MEFV Gene 
SUMMARY 
MEFV gene was first identified as the candidate gene for Familial Mediterranean 
Fever (FMF),which proceed with serosal inflammation and abdominal pain. Most 
common MEFV mutations are E148Q, M680I, M694V, M694I, and V726A which 
account for the 70% of the disease chromosomes. Among these mutations, only 
E148Q was reported to be associated with a milder phenotype of the disease. E148Q 
mutation lies within the second exon of MEFV gene and causes a nucleotide 
substitution of Guanine to Cytosine at nucleotide position 442. E148Q mutation was 
reported to increase MEFV expression whereas other MEFV-related mutations were 
shown to decrease MEFV expression. The milder phenotype in the presence of 
E148Q mutation is thought to be due to its increasing effect on MEFV gene 
expression. 
The electronical analysis of MEFV gene with bioinformatic tools, gives a CpG island 
spanning the second exon of MEFV gene. Moreover, within this CpG island, E148Q 
mutation causes the elimination of one CpG dinucleotide. This study is focused on 
the relationship between the methylation pattern of second exon of MEFV gene in 
relation with the E148Q mutation. 
The techniques used to identify this DNA methylation pattern are Methylation 
Specific PCR (MSP) and Bisulfite Sequencing (BS). Methylation specific PCR was 
used to obtain a preliminary data of DNA methylation at the second exon of MEFV 
gene, whereas methylation quantification was performed by direct bisulfite 
sequencing. 
Consequently, in this study, the methylation pattern of the second exon of MEFV 
gene was determined. This methylation pattern was compared between E148Q 
heterozygotes and wildtype controls as well as FMF samples and healthy controls. A 
significant decrease of CpG methylation at the E148Q site was observed in 
 xi 
 
heterozygotes compared to wildtype samples. No significant difference was found in 
the methylation pattern of the second exon of MEFV gene between FMF samples 
and healthy controls. 
DNA methylation patterns of wildtype and E148Q heterozygote samples were also 
compared with MEFV expression levels determined by another study of human 
genetics group. Methylation level of the CpG dinucleotide at E148Q site found to be 
significantly associated with MEFV expression level. 
In addition, DNA methylation of the second exon was compared between FMF and 
healthy samples. Within the CpG sites analyzed, no significant difference of DNA 
methylation was found at CpG dinucleotides between FMF samples and controls 
except that at three positions DNA methylation was 10-15% lower in FMF patients. 
 xi 
 
MEFV Geninin in vivo Metilasyon Çalışmaları 
ÖZET 
MEFV geni ilk olarak serozal iltihaplanma ve karın ağrısı ile ilerleyen Ailevi 
Akdeniz Ateşi (AAA) hastalığıyla ilişkili gen olarak karakterize edilmiştir. En sık 
gözlenen MEFV mutasyonları E148Q, M680I, M694V, M694I ve V726A olup 
hastalıkla ilgili kromozomların %70’ini oluştururlar. Bu mutasyonlar arasında yalnız 
E148Q mutasyonunun hastalığın daha hafif geçmesini sağlayıcı rolü olduğu 
bilinmektedir. E148Q mutasyonu MEFV geninin ikinci ekzonunda bulunmakta olup 
442. pozisyondaki guanine nükleotidini sitozine çevirmektedir. Diğer MEFV 
mutasyonları MEFV gen ifadesini azaltırken sadece E148Q mutasyonunun MEFV 
gen ifadesini artırdığı bildirilmiştir. E148Q’ya bağlı gen ifadesi artışının FMF 
hastalığının daha hafif geçmesiyle ilişkili olduğu düşünülmektedir. 
MEFV geninin elektronik ortamda biyoinformatik araçlarla analizi genin ikinci 
ekzonunu içine alan bir CpG adacığı olduğunu göstermektedir. Bununla birlikte bu 
CpG adacığının içinde yer alan E148Q mutasyonu bir CpG dinükleotidini ortadan 
kaldırmaktadır. Bu çalışma MEFV geninin ikinci ekzonunun metilasyon paterni ile 
E148Q mutasyonu arasındaki ilişkiye odaklanmıştır. 
DNA metilasyon paterninin aydınlatılması için kullanılan teknikler metilasyona özel 
polimeraz zincir reaksiyonu (PZR) ve bisülfat dizilemesi (BD) yöntemleridir. 
Metilasyona özel PZR yöntemi MEFV geninin ikinci ekzonununun metilasyonu 
hakkında ön bilgi edinmek amacıyla yapılmış olup, bisülfat dizilemesi yoluyla da 
metilasyonun kantifikasyonu yapılmıştır. 
Bu çalışmada sonuç olarak MEFV geninin ikinci ekzonunun metilasyon paterni 
belirlenmiştir. Bu metilasyon paterni E148Q heterozigotları ile yabanıl genotipe 
sahip gruplar arasında ve AAA hastaları ile sağlıklı kontroller arasında 
karşılaştırılmıştır. E148Q mutasyonunun denk geldiği CpG dinükleotidinde yabanıl 
genotipe kıyasla E148Q heterozigotlarında belirgin bir düşüş gözlenmiştir. Bununla 
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birlikte, AAA hastaları ile sağlıklı kontroller arasında MEFV geninin ikinci 
ekzonunun metilasyonu açısından kayda değer bir fark bulunamamıştır. 
Yabanıl tip ve E148Q heterozigot örneklerin DNA metilasyon paterni bu örneklerin 
daha önce İnsan Genetiği grubu tarafından belirlenmiş MEFV gen ifadesi seviyeleri 
ile karşılaştırılmıştır. E148Q dinükleotidinin denk geldiği CpG adacığının metilasyon 
seviyesi ile MEFV gen ifadesi seviyeleri ile karşılaştırılmıştır. E148Q 
dinükleotidinin denk geldiği CpG adacığının metilasyon seviyesi ile MEFV gen 
ifadesi arasında önemli bir ilişki bulunmuştur.  
Buna ek olarak, ikinci ekzonun metilasyonu FMF hastaları ve sağlıklı kontrol grubu 
arasında kıyaslanmıştır. İki grup arasında incelenen CpG bölgelerinde metilasyon 
açısından kayda değer bir fark bulunmamıştır ancak üç CpG bölgesinde DNA 
metilasyonu FMF hastalarında % 10-15 daha az olarak gözlenmiştir. 
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1. INTRODUCTION 
1.1. THEORETICAL PART 
1.1.1. FMF AND MEFV GENE 
1.1.1.1. FAMILIAL MEDITERRENEAN FEVER DISEASE 
Familial Mediterranean Fever (FMF) is classified as a member of hereditary periodic 
fever syndromes, which are also known as autoinflammatory disorders [1]. FMF 
isreported to be an autosomal recessive disorder commonly seen in people of 
Mediterranean origin including Armenians, Sephardi and Ashkenazi Jews as well as 
Turks and Arabs [2]. Typical symptoms include development of transient fever and 
inflammation inserosal membranes, accompanied by abdominal pain [3]. Untreated 
cases usually develop amyloidosis together with renal failure,which is the primary 
complication of FMFdisease [4]. Clinical diagnosis is based on these periodically 
seen attacks of inflammation and amyloidosis in more serious cases. In addition to 
attacks, MEFV mutations are usually screened to support diagnostic findings. 
Treatment of the diease is based on daily colchicine therapy. In majority of the cases 
treated with colchicine, it is observed that FMF attacks are reduced or completely 
prevented. It was also reported that colchicine therapy is preventive against FMF-
related amyloidosis  [2]. 
1.1.1.2. THE MEDITERRENEAN FEVER GENE, MEFV 
MEFV gene was first characterized to be the candidate gene for Familial 
Mediterrenean  Fever in 1997 by International FMF Consortium [5]. In the same 
year, French FMF Consortium reported that the nucleotide changes concentrated at 
the carboxy-terminal of the MEFV gene are responsible for FMF disease [6]. 
Spanning 16kb region on the human genome, MEFV gene is located on chromosome 
16p, and is composed of 10 exons [7]. The gene codes for a 3.7kb transcript [5, 9] 
and expressed mainly in neutrophils, eosinophils, and cytokine activated monocytes 
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[8,9].MEFV expression was shown to be increased by activators of inflammation 
including Tumor Necrosis Factor Alpha and Interferon gamma, which led to 
speculations about an essential role of this gene in the inflammatory response [14]. In 
addition, CD34 positive hematopoietic stem cells were shown to be induced towards 
granulocytic lineage when MEFV was expressed at myelocyte stage, which assigns a 
role to MEFV genein granulocytic lineage specification [9]. 
1.1.1.3. STRUCTURE AND FUNCTION OF PYRIN, THE PROTEIN 
PRODUCT OF MEFV GENE 
MEFV gene codes for a 781 aminoacid protein named pyrin / marenostrin [10]. 
Denomination was made on the basis of Latin and Greek words where pyrin means 
fever (in Greek) and marenostrin means Mediterranean Sea (in Latin) [11]. 
Marenostrin protein contains four domains, which are PYD domain (Pyrin Domain, 
N Terminal Domain), B30.2 domain (C Terminal Domain, PRYSPRY domain), the 
Bzıp transcription factor basic domain and B-box zinc finger coiled coil domain 
(Figure 1.1). Among these domains PYD (pyrin) domain is important to estimate the 
function of the pyrin protein. PYD domains are death domain like structures, which 
have immune system related functions [12]. 
After the prediction of secondary structure of pyrin domain by computational 
techniques, pyrin domain is proposed to be a member of a superfamily which contain 
caspase activation and recruitment domains (CARDs), death domains (DDs), and 
death effector domains (DEDs) [15]. 
Another domain of pyrin protein, B-box zinc finger coiled coil domain, is capable of 
making homodimers and heterodimers with other proteins, whereas the pyrin (PYD) 
domain makes only homodimers with other pyrin domains [15]. 
The PRYSPRY (B30.2) domain is a very common protein – protein interaction 
domain which is known to interact with approximately 500 different proteins. This 
domain is commonly found in proteins, which have immune system related functions 
like cytokine signaling. In pyrin protein, FMF related mutations are concentrated on 
this domain and nearly all of these mutations are reported to be on sites of flexible 
protein binding loops [15]. 
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Figure 1.1 Domains of pyrin protein 
Pyrin protein was shown to interact with a number of other PYD domain containing 
proteins via PYD/PYD domain interactions. The multi-PYD domain interactions are 
shown to be mediated by an adaptor protein named ASC (apoptosis-associated 
speck-like protein whichcontains a caspase recruitment domain) that has important 
roles on programmed cell death, pro-caspase 1 activation and IL-1beta processing as 
well as triggering NF-kappaB response [12]. Depending on these findings, pyrin is 
thought to be involved in inflammation and neutrophil apoptosis [12, 13]. 
Furthermore, Pyrin was suggested to be a negative regulator of granulocyte-mediated 
inflammation [15]. Although the mutant form of pyrin is thougt to prevent 
programmed cell death and cause high IL-1beta levels, which lead to inflammation 
(Figure 1.2), no difference was detected between the binding of mutated and 
wildtype pyrin by means of their association with ASC which indicate an alternative 
pathyway to ASC mediated pyrin function [2]. 
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Figure 1.2 Estimated model of pyrin action in IL-1beta mediated inflammation [16] 
In another study, Chae et al. created transgenic mice, which express mutant pyrin 
protein and observed lipopolysaccharide induced fever and inflammation. In 
homozygous state, the mutation was reported to increase lethality. Activated 
macrophages of these mice showed higher amounts of activated caspase 1 and IL-
1beta (Figure 1.3)[19]. Thedata all together place pyrin protein in myelomonocytic-
specific proinflammatory pathway triggered by lipopolysaccharides and some anti-
inflammatory factors including specific type of interleukins [18]. 
 
Figure 1.3 Proposed model of Pyrin B30.2 domain and Caspase-1 interaction [8] 
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Pyrin protein has two possible nuclear localization signalsin its sequence (amino 
acids 419-422, and 420-437) identified by bioinformatic softwares [17]. Besides 
these signals, pyrin shows homology to some regulators of transcription. Depending 
on these facts, Mansfield et al.proposed that pyrin may also be a regulator of 
transcription [14]. 
To date, one common alternatively spliced form of pyrin is defined, which lacks the 
second exon and causes an in-frame spliced form. Full lenth pyrin was shown to be 
localized in the entire cytoplasm whereas the spliced form is mainly concentrated in 
the nucleus. It was also shown that elimination of the two nuclear localization signals 
does not affect the nuclear localization of the spliced form suggesting an overall 
regulatory function of the lacking domain on the subcellular localization of pyrin 
[17]. 
In another study, the relationship between pyrin and colchicine responsiveness was 
studied. What makes FMF differ from other periodic fever syndromes is the 
colchicine responsiveness. Pyrin is thought to be involved in a colchicine – 
responsive inflammatory pathway. The colchicine action is not related to granulocyte 
activity at the inflammation site but increase in the FMF related inflammatory 
infiltrate. Low doses of colchicine does not affect the total length of microtubule but 
constricts interchange of tubulin dimers at microtubule ends whereas high levels of 
colchicine inhibits plus end polymerization. Colchicine is supposed to have a role on 
microtubule dynamics in granulocytes which leads to poor adhesion and migration 
capability [14]. In addition to this data, Pyrin was found to be associated with 
cytoskeletal elements including mictotubules and actin filaments by Mansfield et 
al.They have found a cytoplasmic localization of full length pyrin, and detected 
colocalizaiton of pyrin with actin and mictobule cytoskeleton within the cell. They 
have also shown that pyrin – microtubule interaction was provided via the N terminal 
domain (B30.2) of pyrin protein [14]. To investigate the colchicine responsiveness in 
FMF, further studies need to be done. 
1.1.1.4. COMMON MEFV MUTATIONS AND MEFV EXPRESSION LEVELS 
Nearly 30 sequence variants of MEFV gene was reported to be associated with FMF 
[20]. Five FMF mutations, M694V, V726A, M694I, M680I and E148Q correspondto 
aproximately 75% of FMF alleles [15]. Among severe number of MEFV mutations, 
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thisfivemutationsseem to be responsible for most of the FMF cases. Except from 
E148Q mutation, which was reported to cause a milder phenotype in FMF, other four 
mutations located in the 10th exon which correspond to PRYSPRY domain of pyrin 
protein [15]. 
The relationship between FMF disease and MEFV mutations remains to be clarified. 
Although FMF was reported to be an autosomal recessive disorder, there are non-
symptomatic cases which carry two mutant alleles of MEFV (either homozygous for 
one mutation or compound heterozygotes). On the contrary, some FMF cases are 
reported not to have any MEFV mutations [2]. There are suggestions about the type 
of the mutation and FMF disease relation. The most commonly seen form of MEFV 
mutation among FMF patients is M694V, which is tought to cause more drastic 
symptoms in FMF with a ranging allele frequency among populations like 45% in 
Armenians [21], 52% in Turkish population [22], and 80% in Iraqi and North African 
Jewish population [23]. Located at the second exon of MEFV gene, E148Q mutation 
was reported to be most frequently seen sequence variant in general population (non-
FMF subjects) [7]that is related with the milder phenotype in FMF [2].  
To establish the relationship between certain MEFV mutations and FMF disease 
pathology, several gene expression studies were done. In 2002, Notarnicola et al. 
studied the relationship between MEFV expression levels of peripheral blood 
leukocytes and FMF. They reported that MEFV expression levels are lower in FMF 
patients compared to non-founder controls. According to their results, M694V 
mutation was related with considerably lower levels of MEFV expression. In 
addition, they have shown that the number of carrier M694V alleles are important in 
MEFV expression levels. Homozygote mutant cases show lower MEFV expression 
levels than heterozygotes. Besides, showing FMF symptoms is a factor that decreases 
MEFV expression among M694V mutation carriers [24]. In another study, Üstek et 
al. confirmed that MEFV expression is lower in FMF patients compared to non-
founder control group, and further studied MEFV expression levels of peripheral 
blood leukocytes in FMF patients during asymptomatic period and FMF attacks. 
They have reported that MEFV expression levels were drastically decreased during 
attacks of FMF [25].On the other hand, patients carrying E148Q mutation showed 
higher MEFV expression than other FMF patients [24]. This data was consistent with 
the suggestions of Touitou (2001) about E148Q mutation and its protective effect in 
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FMF patients. In that study it was reported that 55% of the cases who are 
homozygous for E148Q did not show any disease symptoms and never developed 
amyloidosis [26]. Mimouni et al. also founded that among serious FMF cases, 
E148Q carriers did not developed amyloidosis [27]. In contrast with these E148Q 
carriers, compound heterozygotes with E148Q commonly show amyloidosis 
suggesting a more severe effect of this allele in compound heterozygote form [26].  
Touitou proposed that the genotype phenotype correlation in FMF needs further 
study to be established, like exploration of complex alleles, modifier loci, genetic 
heterogenity as well as potential epigenetic regulators. In the case of E148Q 
mutation, causes of the phenotypic difference between E148Q carriers and 
compound heterozygotes remain to be established. It was suggested that some 
unknown genetic and epigenetic mechanisms may present behind E148Q case, and 
E148Q was defined as a functional polymorphism by this group [26]. 
1.1.2. DNA METHYLATION AND EPIGENETICS 
1.1.2.1. EPIGENETIC MECHANISMS IN HIGHER EUKARYOTES 
Epigenetics is defined as the non-genetic mechanisms, which has roles on gene 
expression. Epigenetic changes include histone modifications and DNA methylation 
[30]. Most commonly studied epigenetic mechanism is DNA methylation, which is 
involved in gene silencing in mammals [28]. DNA methylation is known to have 
effects on cellular mechanisms like development, X chromosome inactivation and 
imprinting, inhibition of foreign DNA, T cell action, aging, and memory [29]. 
CpG dinucleotides are not equally distributed throughout the human genome. Most 
of the CpG dinucleotides are concentrated at the promoter sites of genes. CpG 
clusters with a GC content of above 55% is termed as CpG islands. They are usually 
bigger than 0.5kb and have a minimum observed/expected CpG density of 0.65 [30]. 
DNA methylation occurs at the cytosine residues of CpG dinucleotides in the 
mammalian genome. Normally, 50 to 70 percent of CpG sites are methylated in the 
human genome [30]. 
DNA methylation is carried out by special enzymes called DNA metyhltransferases 
(DNMTs). DNMTs transfer the methyl group from S-adenosylmethione (SAM) to 
5th carbon of cytosine nucleotide (Figure 1.4). Different types of DNMTs are 
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identified to date. DNMT1 is the maintanance methylase which is responsible for 
copying original methylation pattern of parental DNA to newly formed DNA during 
replication. Other methylases are DNMT3a and DNMT3b, which are identified as de 
novo methylases and responsible for methylation of unmethylated DNA usually in 
embryonic stem cells [30]. 
 
Figure 1.4 Cytosine methylation by DNA methyltransferases 
In addition to DNA methylation, histone modifications play important roles in terms 
of epigenetic regulation. 5 types of histones (H2A, H2B, H3 and H4) come together 
to form the nucleosome structure, which is then surrounded by a 146 bp DNA. 
Modifications of these histone proteins like histone 3 lysine 4 trimethylation, histone 
3 lysine 9 trimethylation, and histone acetylation at certain aminoacids trigger 
chromatin remodelling mechanisms, which is responsible for tight or loose 
packaging of chromatin and indeed causes gene expression changes (Figure 
1.5) [30]. 
 
Figure 1.5 Histone modifications and chromatin state 
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When the methyl group is transferred from SAM, the resulted molecule is called S-
adenosylhomocysteine (SAH), which is concerted to homocysteine by removal of 
adenosine part. For maintanance of SAM levels, SAH should be converted to 
methionine, which is the precursor of SAM. This process is closely related to folic 
acid, since it is needed for conversion of SAH to methionine. Elevated levels of 
homocysteine due to low folate intake was reported to be associated with more than 
five cancer types, cardiovascular diseases, cerebrovascular diseases,  diabetes, and 
developmental as well as neurological disorders [29]. 
De novo methylation of cancer related genes including tumor suppressors are widely 
studied, but the effects of DNA methylation on aging and familial diseaseas remains 
to be established [28]. 
1.1.2.2. GENE EXPRESSION REGULATION VIA DNA METHYLATION 
DNA methylation is a common transcriptional regulation mechanism in mammals. 
Effects of DNA methylation on gene expression was commonly studied in the 
promoters of some disease-associted genes including several types of cancers. To 
date, severe number of cases were shown about the effects of aberrant DNA 
methylation of promoters on disease-associated gene expression changes. For 
example, the increase of promoter methylation in tumor suppressor gene p53 was 
reported to be associated with several cancer types including hepatocellular 
carcinoma [32], breast cancer [33], and lung cancer [34]. In addition to promoter 
methylation, methylation status of intronal or exonal CpG islands are started to be 
studied and reported that these might be functional. In a study made by Babidge et 
al., it was shown that in colorectal carcinomas, the second exon of the bcl-2 gene is 
aberrantly methylated [35]. In addition, Kempster et al. reported a methylation of the 
second exon of p16 gene is related with oesophageal cancer [36].  
In addition to promoter methylation, transposable elements commonly contain 
methylated CpG sites which is often seen in intronic regions. Lorincz et al studied 
whether intragenic methylation has an effect on transcriptional efficiency and 
reported a slight decrease in constracts methylated in a region downstream of the 
promoter, compared to unmethylated construct. This finding shows that DNA 
methylation in the regions downstream of the promoters may also have an effect on 
transcriptional efficiency. The mechanism of intragenic methylation-related decrease 
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of transcriptional efficiency was reported to be related with altered chromatin 
structure at methylated sites [37].  
In addition, methylation at the downstream sites of a promoter was shown to 
decrease Pol II density at the methylated sites, which indicate a decrease in the 
transcriptional elongation step;  whereas there was no difference of PolII density at 
the promoter sites of methylated and unmethylated constructs which indicate that 
transcriptional initiation was not affected by DNA methylation at the sites 
downstream of the promoter. In short, methylated DNA at the downstream site of a 
promoter does not affect transcriptional initiation efficiency but decreases elongation 
efficiency due to the alteration in the state of the chromatin [37]. 
Moreover, DNA methylation in intragenic regions is began to be studied and 
significant associations was shown in different studies between intragenic 
methylation and gene expression. In one of these studies, Okitsu et al studied 
methylation of a luciferase transcription unit and reported that intragenic DNA 
methylation at this transcriptional unit is more effective on gene expression rather 
than promoter methylation. Shortly, intragenic DNA methylation can be as important 
as promoter methylation [38]. 
Besides intronal and exonal DNA methylations, there are also cases of allele specific 
changes in DNA methylation. Polesskaya et al. reported that allele-specific DNA 
methylation in 5HT2AR gene regulates the expression of this gene via establishing 
methylation difference between C and T alleles of a polymorphism in its first 
exon [39]. 
1.2. PRACTICAL PART 
1.2.1. SNP GENOTYPING 
Single nucleotide polymorphisms were first studied in 1980s by using restriction 
enzymes to discrminate between wildtype and polymorphic allele depending on the 
fragment length after restriction enzyme digestion [31].  
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1.2.1.1. POLYMERASE CHAIN REACTION 
Polymerase chain reaction is a technique used for in vitro amplification of target 
DNA sequences. Short oligonucleotide primers are used to prime the DNA synthesis 
reaction by heat-stable DNA polymerases. Subsequent cycling od denaturation, 
annealing and extension steps by thermal cycling, target DNA sequence is 
logarithmically amplified. PCR is used in many applications in molecular biology 
including genotyping, cloning, mutagenesis, and DNA sequencing [40]. 
1.2.1.2. RESTRICTION ENZYME DIGESTION 
Restriction endonucleases are special enymes, which are capable of recognizing 
specific sequences on DNA and cutting of that DNA [41]. Thesere are two types of 
restriction endonucleases called type I and type II restriction enzymes. Type I 
endonucleases are capable of cutting the DNA within their recognition site on the 
DNA, whereas type II endonucleases recognize a specific DNA sequence and cut the 
DNA at a neighbourhood site of that sequence. 
Restriction endonucleases are used in several molecular biology applications 
including genotyping of single nucleotide polymorphisms where the SNP eliminates 
or introduces a restrciton site on the DNA. Depending on the type, these SNPs 
change the restriction fragment patterns and commonly used for detection of 
genotypes in molecular biology [42]. 
1.2.1.3. AGAROSE GEL ELECTROPHORESIS 
Agarose gel electrophoresis is a commonly used and highly effective technique to 
separate, identify, and purify DNA fragments usually within the range of 0.5- to 25-
kb. The basic procedure in electrophoresis has three main stages, which are gel 
preparation with a determined agarose concentration useful to separate DNA 
fragments of wanted sizes, loading of DNA samples into the wells of the gel and 
running of the gel at a determined voltage and  time period which will allow 
complete separation of DNA fragments and staining of the gel with ethidium 
bromide and visualization by illumination with UV light [43, 44].  
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1.2.2. DNA METHYLATION DETECTION 
1.2.2.1. BISULFITE TREATMENT 
The addition of methyl groups to cytosine nucleotide of DNA is a commonly studied 
epigenetic DNA marker. Most of the technologies used for DNA methylation 
analysis are based on a chemical reaction, named ‘bisulfite treatment’, which makes 
methylation-dependent nucleotide changes by selective chemical conversion of non-
methylated cytosine to uracil. In bisulfite treatment technique; all cytosine bases, 
which are non-methylated are converted to uracil but all methylated cytosine bases 
remain as cytosines. Bisulfite treated DNA than can be analyzed by using severe 
number of techniques like methylation specific PCR or direct bisulfite 
sequencing [45]. 
1.2.2.2. METHYLATION SPECIFIC PCR 
Methylation Specific PCR (MSP) is a technique that used to discriminate between 
methylated and unmethylated bisulfite treated DNAs. The technique is based on 
desiging two sets of primers (M and U primers) each specific to certain type of DNA 
(methylated or unmethylated, bisulfite treated). M primers amplify only methylated, 
bisulfite treated DNA but not unmethylated, bisulfite treated DNA; whereas U 
primers amplify only unmethylated, bisulfite treated DNA but not methylated, 
bisulfite treated DNA [46, 47].  
1.2.2.3. BISULFITE SEQUENCING 
Bisulfite sequencing is a technique based on the amplification of methylated, 
bisulfite treated and unmethylated, bisulfite treated DNA fragments together 
followed by sequencing. Bisulfite sequencing can be applied directly to amplified 
DNA fragments (direct bisulfite sequencing) or by cloning of the PCR product and 
screening colonies by sequencing which is based on a statistical manner [48]. 
1.3 AIM OF THE STUDY 
The aim of this study was to investigate the methylation pattern of the second exon 
of MEFV gene. In addition, two subgroups (E148Q heterozygotes and wildtypes) are 
selected to compare the DNA methylation patterns of the second exon since E148Q 
mutation eliminates a CpG site within the second exon. Furthermore, DNA 
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methylation levels of the CpG dinucleotide at the E148Q site was compared between 
wildtypes and E148Q heterozygotes. Since E148Q was known to increase MEFV 
expression, the methylation data was also compared in relation with MEFV gene 
expression determined by another study in our group. For further investigation about 
FMF disease and DNA methylation, DNA methylation levels of FMF samples and 
healthy controls were compared in connection with MEFV expression levels in these 
two groups. 
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2. MATERIALS AND METHODS 
2.1. MATERIALS AND LABORATORY EQUIPMENTS 
2.1.1. EQUIPMENTS 
The laboratory equipments used in this study are listed in Appendix A. 
2.1.2. CHEMICALS, ENZYMES AND MARKERS 
The chemicals, enyzmes and markers used in this study are given in Appendix B. 
2.2. CpG ISLAND ANALYSIS OF MEFV GENE 
MEFV genomic sequence was analyzed in terms of CpG island content by using 
CpG island searcher software of University of Southern California. An illustration of 
the program screen is given in figure 2.1. 
 
Figure 2.1: Illustration of CpG island software 
2.3. DNA ISOLATION 
2.3.1. COLLECTION AND STORAGE CONDITIONS OF BLOOD SAMPLES 
Peripheral blood was obtained from people which come routine controls in 
Cerrahpaşa Medical Faculty Geriatrics Polyclinic. Blood samples were preserved in 
EDTA containing 5cc vacuum tubes, and stored at -20°C for short term and at -80°C 
for long term storage. 
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2.3.2. DNA ISOLATION FROM WHOLE BLOOD 
The DNA isolation was performed by using Migration System 8Lx Instrument. DNA 
isolation kits were supplied by Precision System Science. DNA was isolated in an 
automated system and nearly 4 ml of blood was used for each sample. Isolated DNAs 
were kept at -20°C.  
2.3.3. SPECTROPHOTOMETRIC CALCULATION OF DNA 
CONCENTRATIONS 
Isolated genomic DNAs were diluted 1:100 ratio with sterile dH2O to a total volume 
of 500µl and absorbance values at 260nm, 280nm, and 320nm were measured. 
Concentration and DNA quality calculations from absorbance values are done 
according to the equations 2.1 and 2.2. 
 
DNA Concentration (ng/µl) = (A260 - A320) x Dilution Factor                           (2.1) 
DNA Quality = (A260 – A320) / (A280 – A320)                                                   (2.2) 
2.3.4. PREPARATION OF WORKING ALIQUOTS OF GENOMIC DNA 
To prepare working aliquots of 50ng/µl genomic DNAs,  stock DNAs were diluted 
by using the equation 2.3. 
 
M1xV1=M2xV2                                                                                                     (2.3) 
 
Where, 
M1=Stock DNA Concentration 
V1=Volume of DNA gotten from Stock 
M2=Aliquot DNA Concentration (50ng/µl) 
V2=Final aliquot volume (500 µl) 
2.4. E148Q GENOTYPING 
2.4.1. POLYMERASE CHAIN REACTION (PCR) 
Polymerase chain reaction (PCR) was used to amplify the corresponding sequence 
within the second exon of MEFV gene which contain E148Q site. For PCR 
amplification, 50ng/µl working aliquots of genomic DNA was used as a template. To 
amplify 244 bp region containing E148Q site two oligonucleotide primers were used 
which are given in table 2.1.  
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Table 2.1: E148Q genotyping primers 
Forward Primer 5'-ATATTCCACACAAGAAAACGGC-3' 
Reverse Primer 5'-GCTTGCCCTGCGCG-3’ 
 
PCR mix used for the amplification of 244bp DNA fragment containing E148Q site 
is given in table 2.2. 
 
Table 2.2. E148Q PCR mix 
Stock Conc. PCR Ing. 1X Final Conc. 
10X Taq Buffer with KCl 
without Mg 
2 µL 1X 
2 mM dNTP Mix 0.4 µL 40 µM 
10 µM Forward Primer 1 µL 0.5 µM 
10 µM Reverse Primer 1 µL 0.5 µM 
50ng/µL Genomic DNA 2 µL 5 ng/µL 
5u/µL Taq DNA Polymerase 0.2 µL 0.05 U/µL 
25 mM MgCl2 1.5 µL 1.875 mM 
5X Q Solution 4 µL 1X 
 dH2O 7.9 µL  
 TOTAL 20 µL  
 
PCR program of E148Q genotyping PCR is given in table 2.3. 
 
Table 2.3: Program of E148Q PCR 
Initial Denaturation 96°C 5 min  
Denaturation 96°C 30 sec  
X 5 Annealing 64°C 30 sec 
Extension 72°C 30 sec 
Denaturation 96°C 30 sec  
 X 35 Annealing 62°C 30 sec 
Extension 72°C 30 sec 
Final Extension 72°C 10 min  
Final Hold 4°C ∞  
 
2.4.2. AGAROSE JEL ELECTROPHORESIS FOR DETECTION OF PCR 
AMPLIFICATION 
The expected DNA fragment length after PCR amplification was about 250 bp which 
is estimated to be clearly detectible in 1% agarose gel. To prepare 1% agarose gel in 
a mini electrophoresis system, 0.5 g agarose was dissolved in 50 µl 1X TBE buffer. 
0.5 μg/mL ethidium bromide concentration was used for the gel. For each sample, 5 
µl of PCR amplicon was mixed by 1 µl of 6X loading dye (Fermentas). As a 
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standard, Gene Ruler 1 kb DNA Ladder (Fermentas) was used to estimate the PCR 
amplicon sizes. Electrophoresis conditions were 40 minutes at 120V (12V/cm of 
gel). Pictures of the gels were taken under UV light with a transilluminator, by the 
help of UV PhotoMW software. 
2.4.3. RESTRICTION ENZYME DIGESTION OF PCR PRODUCTS 
Because the E148Q mutation eliminates a new AvaI restriction site from MEFV 
nucleotide sequence, PCR amplicons were digested with AvaI restriction 
endonuclease to determine the genoype of each DNA sample. Restriction digestion 
mix was prepared according to the table 2.4. 
Table 2.4: Restriction mix for AvaI digestion 
Ingredients Amount Final Concentration 
10X Reaction Buffer  2 µl 1X 
AvaI Restriction Enzyme 
(10U/µl) 
1 µl 0.5U/µl 
PCR Amplicon 12 µl - 
dH2O 5 µl - 
TOTAL 20 µl  
 
Restriction enzyme digestion was performed at 37°C for overnight followed by 15 
min incubation at 80°C for restriction enzyme inactivation. The expected AvaI 
restriction digestion pattern of 244bp PCR amplicon is given in table 2.5. 
 
Table 2.5: Restriction fragments of E148Q alleles 
Wild Type 3 fragments (92+83+69 bp) 
Mutant 2 fragments (161+83 bp) 
 
2.4.4. DETERMINATION OF RESTRICTION PATTERN BY AGAROSE 
GEL ELECTROPHORESIS 
Overnight digested samples were run on 3% agarose gel. 12µl of each sample was 
mixed with 2µl of 6X loading dye and loaded to the gel together with Gene Ruler 
Low Range DNA Ladder (Fermentas). Agarose gel was run at 100V for 1 hour for 
appropriate separation of digested DNA fragments. The gel pictures are taken by 
using UV PhotoMW software. 
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2.4.5. DETERMINATION OF GENOTYPES 
Analysis of restriction pattern for all samples are done by comparing each restriction 
pattern according to the electronic digestion pattern shown below: 
 
Figure 2.2: Expected restriction patterns of E148Q genotypes 
2.5. DNA METHYLATION ANALYSIS 
2.5.1. BISULFITE TREATMENT 
For the analysis of DNA methylation patterns of 27 DNA samples (15 wildtype, 3 
E148Q heterozygotes and 9 FMF samples) bisulfite treatment technique was used for 
chemical conversion of unmethylated cytosines to uracile nucleotide by deamination 
whereas methylated cytosines are not converted. Consequently, bisulfite treatments 
leads to two different DNAs for methylated and unmethylated forms of the same 
DNA fragment. 
Since the initial DNA concentration used in this technique is limited because of the 
sensitive parameters of bisulfite conversion efficiency, 1µg of each DNA sample was 
used for bisulfite conversion (The supplier’s recommended DNA amount is 1ng to 
2µg). QIAGEN EpiTect bisulfite kit was used to perform bisulfite conversion. Main 
steps of the protocol include sodium bisulfite conversion of unmethylated cytosines, 
binding of the DNA to EpiTect column, washing and desulfonation steps, and finally 
elution of bisulfite converted DNA. The detailed protocol is given below: 
Before starting to bisulfite reaction,  
• 30 ml ethanol (96–100%) was added to Buffer BW and stored at room 
temperature (15–25°C). The bottle was inverted several times before starting the 
procedure.  
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• 27 ml of Ethanol (96–100%) was added to Buffer BD and stored at room 
temperature. The bottle was inverted several times before starting the procedure. 
• 310 μl RNase-free water was added into the lyophilized carrier RNA (310 μg) 
to obtain a 1 μg/μl solution. The carrier RNA was dissolved thoroughly by vortexing. 
Dissolved carrier RNA was added to Buffer BL.  
Bisulfite Conversion Protocol: 
• DNA to be used in the bisulfite reaction was thawn in room temperature.  
• Bisulfite Mix was dissolved by adding 800 μl RNase-free water to each 
aliquot. Tubes are vortexed until the Bisulfite Mix is completely dissolved. 
• Bisulfite reactions in 200 μl PCR tubes were prepared according to the table 
2.6. 
Table 2.6: Bisulfite reaction mix 
Bisulfite Reaction Components   Component Volume per reaction (μl) 
DNA solution 20 (1µg) 
RNase-free water - 
Bisulfite Mix (dissolved) 85 
DNA Protect Buffer                           35 
Total volume                                      140 
• PCR tubes are closed and the bisulfite reactions are mixed thoroughly.  
• Bisulfite DNA conversion was performed using a thermal cycler according to 
the program given in table 2.7. 
Table 2.7: Bisulfite reaction program 
Step Time Temperature 
Denaturation 5 min 99°C 
Incubation 25 min 60°C 
Denaturation 5 min 99°C 
Incubation 85 min 60°C 
Denaturation 5 min 99°C 
Incubation 175 min 60°C 
Hold hold 20°C 
 
• PCR tubes containing the bisulfite reactions were placed into the thermal 
cycler. Incubation was started with the program above. 
• After the bisulfite conversion is complete, PCR tubes containing the bisulfite 
reactions were centrifuged briefly, and the complete bisulfite reactions were 
transferred to clean 1.5 ml microcentrifuge tubes. 
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• 560 μl freshly prepared Buffer BL containing 10 μg/ml carrier RNA was 
added onto the bisulfite reactions. The solutions are mixed by vortexing and 
centrifuge briefly. 
• EpiTect spin columns are placed on collection tubes. The whole mixture from 
previous step was transferred  into the EpiTect spin column. 
• The column was centrifuged at maximum speed for 1 minute. Flow-through 
was discarded, and the spin column was placed back into the collection tube. 
• 500 μl Buffer BW (wash buffer) was added into the spin column, and 
centrifuged at maximum speed for 1 min. The flow-through was discarded, and the 
spin column was placed back into the collection tube. 
• 500 μl Buffer BD (desulfonation buffer) was added into the spin column, and 
incubated for 15 min at room temperature.  
• The column was centrifuged at maximum speed for 1 min. The flow-through 
was discarded, and the spin column was placed back into the collection tube. 
• 500 μl Buffer BW was added and column was centrifuged at maximum speed 
for 1 min. The flow-through was discarded, and the spin column was placed back 
into the collection tube. This step was repeated two times. 
• The spin column was placed into a new 2 ml collection tube, and centrifuged 
at maximum speed for 1 min to remove any residual liquid. 
• The spin column was placed into a clean 1.5 ml microcentrifuge tube. 20 μl 
Buffer EB was added to the center of the membrane. The purified DNA was eluted 
by centrifugation for 1 min at approximately 15,000 x g (12,000 rpm). 
• Bisulfite treated DNAs were stored at –20°C. 
2.5.2. METHYLATION SPECIFIC PCR 
Methylation specific PCR (MSP) is a technique based on the amplification of 
bisulfite modified DNA with methylation specific primers. During the entire study, 
methylated, bisulfite treated DNA-specific primers are named as M primers whereas 
unmethylated, bisulfite treated DNA-specific primers are named as U primers. MSP 
needs two positive control DNAs which are the fully-methylated DNA and 
unmethylated DNA. MSP should be optimized for M and U primers such that M 
primers should only amplify methylated-bisulfite treated DNA but not the 
unmethylated-bisulfite treated DNA. Besides, U primers should amplify only 
 21 
 
unmethylated, bisulfite treated DNA but not methylated, bisulfite treated DNA. 
These conditions are provided by using positive control DNAs and setting the 
stringency of PCR conditions.  
2.5.2.1. AMPLIFICATION OF CONTROL DNA FRAGMENT FROM 
GENOMIC DNA FOR PREPARATION OF UNMETHYLATED MSP 
CONTROL 
To prepare positive control DNA fragments for MSP, two primers were used to 
amplify a 567 bp region including the CpG island spanning the second exon of 
MEFV gene. Human genomic DNA was used as a template. The primer sequences 
used to amplify control DNA fragment is given in table 2.8. Primer locations on 
MEFV genomic sequence are given in figure 2.3. 
Table 2.8: Primers used to amplify control DNA fragment 
Primer Size Tm GC% Sequence Product
MSPkF 21 52.6 42.8 5’-GCTTCATCATTTTGCATCTGG -3’  
567 bp MSPkR 20 54.3 50.0 5’-GATTCGCAGCTGTCTTTTCC -3’ 
 
ctcaggtgatcctcccgcctcggcctcccagagtgccgggaatacaggca 
tgagccaccgcgcccggcccgttgttttcctcaatttctaaactttaata 
tccaaggggattctctctcctctgccctgaatcttgggccctaaacgtgg 
gacagcttcatcattttgcatctggttgtccttccagAATATTCCACACA 
AGAAAACGGCACAGATGATTCCGCAGCGTCCAGCTCCCTGGGGGAGAACA 
AGCCCAGGAGCCTGAAGACTCCAGACCACCCCGAGGGGAACGAGGGGAAC 
GGCCCTCGGCCGTACGGGGGCGGAGCTGCCAGCCTGCGGTGCAGCCAGCC 
CGAGGCCGGGAGGGGGCTGTCGAGGAAGCCCCTGAGCAAACGCAGAGAGA 
AGGCCTCGGAGGGCCTGGACGCGCAGGGCAAGCCTCGGACCCGGAGCCCG 
GCCCTGCCGGGCGGGAGAAGCCCCGGCCCCTGCAGGGCGCTAGAGGGGGG 
CCAGGCCGAGGTCCGGCTGCGCAGAAACGCCAGCTCCGCGGGGAGGCTGC 
AGGGGCTGGCGGGGGGCGCCCCGGGGCAGAAGGAGTGCAGGCCCTTCGAA 
GTGTACCTGCCCTCGGGAAAGATGCGACCTAGAAGCCTTGAGGTCACCAT 
TTCTACAGGGGAGAAGGCGCCCGCAAATCCAGAAATTCTCCTGACTCTAG 
AGGAAAAGACAGCTGCGAATCTGGACTCGGCAACAGAACCCCGGGCAAGG 
CCCACTCCGGATGGAGGGGCATCTGCGGACCTGAAGGAAGGCCCTGGAAA 
TCCAGAACATTCGGTCACCGgtaaattgtgttctttcctactttatatcg 
Gctgcagagaaagaatggctggccgggcacgatagctcatgcctgtaatc 
 
Figure 2.3: Control primer sites on mefv genomic sequence. Upper cases indicate 
exon 2 of MEFV gene whereas lower cases show introns. Underlined nucleotides 
indicate control fragment primer sites. 
PCR mix contents and PCR program used for amplification of control fragment are 
given in tables 2.9 and 2.10. 
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Table 2.9: PCR mix used for amplification of MSP control fragment 
Stock Conc. PCR Ing. X Final Conc. 
10X Taq Buffer with KCl and Mg 2.0µL 1X 
10mM dNTP Mix 0.4µL 0.4mM 
10 µM MSPkF 0.5µL 0.2 µM 
10 µM MSPkR 0.5µL 0.2 µM 
100ng/µL Human Genomic  DNA 1µL 4ng/µL 
5u/µL Taq DNA Polymerase 0.2µL 0.1u/µL 
- dH2O 15.4  
 TOTAL 20 µL  
 
Table 2.10: PCR program used for amplification of MSP control fragment 
Initial Denaturation 94°C 2 min  
Denaturation 94°C 30 sec  
X40 Annealing 50°C 30 sec 
Extension 72°C 30 sec 
Final Extension 72°C 10 min  
Final Hold 4°C ∞  
2.5.2.2. PURIFICATION OF PCR PRODUCT 
The PCR Product was purified bu using QIAGEN Gel Extraction Kit for further 
methylation reactions. PCR purification protocol is given below: 
• 3 volumes of Buffer QG was added to 1 volume of the PCR sample and 
mixed.  
• QIAquick spin column was placed in a provided 2 ml collection tube. 
• To bind DNA, the sample was placed to the QIAquick column and 
centrifuged for 60 seconds. 
• Flow-through was discarded and QIAquick column placed back into the same 
tube. 
• To wash, 0.75 ml of Buffer PE was added to the QIAquick column and 
centrifuged for 60 seconds. 
• Flow-through was discarded and the QIAquick column was placed back into 
the same tube. 
• The column was centrifuged for an additional 1 min. 
• QIAquick column was placed in a clean 1.5 ml microcentrifuge tube. 
• To elute DNA, 50 μl Buffer EB was added to the center of the QIAquick 
membrane and centrifuged for 1 minute.  
• Eluted DNA was further used as unmethylated control for MSP, and also used 
to prepare methylated control for MSP. 
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2.5.2.3. SssI METHYLATION OF CONTROL FRAGMENT FOR 
PREPARATION OF METHYLATED MSP CONTROL 
Preparation of methylated control DNA fragment was performed by SssI methylation 
of previously prepared unmethylated control fragment. 20 μl of unmethylated DNA 
fragment was methylated according to the following protocol on table 2.11. 
Table 2.11: SssI Methylation mix 
Ingredients: Amount 
10X NEB Buffer 2 5 µL 
200X SAM 2 µL 
SssI Methylase 1 µL 
DNA (Control Fragment) 20 µL 
dH2O 22 µL 
Total 50 µL 
 
The reaction mix was prepared and incubated at 37C for 3 hours. After 1,5 hour, 
additional 1 µL of SAM was added into the reaction mix. The final reaction included 
30X SAM. 
2.5.2.4. PURIFICATION OF METHYLATED DNA FRAGMENT 
The PCR Product was purified bu using QIAGEN Gel Extraction Kit in order to 
obtain efficient bisulphite conversion in subsequent steps. 
2.5.2.5. CONFIRMATION OF METHYLATION: 
5 µL of methylated and 5 µL of unmethylated PCR products were digested by BstUI 
for 1 hour. Digestion products are run in 1% agarose gel in 1X TAE buffer.  
2.5.2.6. BISULPHITE TREATMENT OF CONTROL FRAGMENTS 
Both methylated and unmethylated control fragments were subjected to bisulphite 
treatment by using QIAGEN EpiTect bisulfite kit with the protocol given in methods. 
2.5.2.7. MSP PRIMER DESIGN 
There are several bioinformatic programs which can be used for designing MSP 
primers. In this study, MethylPrimer Express software was used to select M and U 
primers specific to a short part of the CpG site in the second exon of MEFV gene. 
After uploading target genomic DNA sequence, the software converts the genomic 
DNA to the bisulfite treated form by considering both the methylated and 
unmethylated forms of the target DNA fragment. Then, it chooses forward and 
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reverse primers on the regions which show most difference between bisulfite treated 
methylated and bisulfite treated unmethylated DNAs (Figure 2.4). These mostly 
different sites are the densely CpG containing sites. Each CpG site correspons to one 
base difference between M and U primers (Cytosine in the M primer and Uracil in 
the U primer, both in the case of forward primers). So, MSP primer selection criteria 
is that they should be selected at CpG containing sites to discriminate between 
methylated and unmethylated DNAs during PCR amplification. 
 
 
Figure 2.4: Methylation Specific Primer areas selected by MethylPrimer Express 
software 
 
U primer sequence is given in table 2.12 whereas primer sites are shown in figure 
2.5. 
 
Table 2.12: MSP U primer sequences 
Primer Sequence Product Size
Left 10 U 5’-TATAAGAAAATGGTATAGATGATTTTGT-3’  
201 bp Right 10 U 5’-CTCTACATTTACTCAAAAACTTCCTCAA-3’ 
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tttaggtgatttttttgttttggttttttagagtgttgggaatataggta 
tgagttattgtgtttggtttgttgttttttttaatttttaaattttaata 
tttaaggggatttttttttttttgttttgaattttgggttttaaatgtgg 
gatagttttattattttgtatttggttgtttttttagAATATTTTATATA 
AGAAAATGGTATAGATGATTTTGTAGTGTTTAGTTTTTTGGGGGAGAATA 
AGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATGAGGGGAAT 
GGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTT 
TGAGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGA 
AGGTTTTGGAGGGTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTG 
GTTTTGTTGGGTGGGAGAAGTTTTGGTTTTTGTAGGGTGTTAGAGGGGGG 
TTAGGTTGAGGTTTGGTTGTGTAGAAATGTTAGTTTTGTGGGGAGGTTGT 
AGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGTTTTTTGAA 
GTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTAT 
TTTTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAG 
AGGAAAAGATAGTTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGG 
TTTATTTTGGATGGAGGGGTATTTGTGGATTTGAAGGAAGGTTTTGGAAA 
TTTAGAATATTTGGTTATTGgtaaattgtgtttttttttattttatattg 
Gttgtagagaaagaatggttggttgggtatgatagtttatgtttgtaatt 
 
Figure 2.5: MSP U primers on unmethylated, bisulfite treated MEFV genomic DNA. 
Upper cases indicate exon 2 of MEFV gene whereas lower cases show introns  
M primer sequence is given in table 2.13 whereas primer sites are shown in figure 
2.6. 
Table 2.13: MSP M primer sequences 
Primer Sequence Product Size
Left 13  M 5’-AAGAAAACGGTATAGATGATTTCGT-3’  
196 bp Right 13 M 5’-CTACGTTTACTCAAAAACTTCCTCG-3’
 
tttaggtgattttttcgtttcggttttttagagtgtcgggaatataggta 
tgagttatcgcgttcggttcgttgttttttttaatttttaaattttaata 
tttaaggggatttttttttttttgttttgaattttgggttttaaacgtgg 
gatagttttattattttgtatttggttgtttttttagAATATTTTATATA 
AGAAAACGGTATAGATGATTTCGTAGCGTTTAGTTTTTTGGGGGAGAATA 
AGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACGAGGGGAAC 
GGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTT 
CGAGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGA 
AGGTTTCGGAGGGTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCG 
GTTTTGTCGGGCGGGAGAAGTTTCGGTTTTTGTAGGGCGTTAGAGGGGGG 
TTAGGTCGAGGTTCGGTTGCGTAGAAACGTTAGTTTCGCGGGGAGGTTGT 
AGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGTTTTTCGAA 
GTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTAT 
TTTTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAG 
AGGAAAAGATAGTTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGG 
TTTATTTCGGATGGAGGGGTATTTGCGGATTTGAAGGAAGGTTTTGGAAA 
TTTAGAATATTCGGTTATCGgtaaattgtgtttttttttattttatatcg 
Gttgtagagaaagaatggttggtcgggtacgatagtttatgtttgtaatt 
 
Figure 2.6: MSP M primers on methylated, bisulfite treated MEFV genomic DNA. 
Upper cases indicate exon 2 of MEFV gene whereas lower cases show introns. 
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2.5.2.8. MSP PCR CONDITIONS 
Methylation specific PCR was performed with the following protocol and program 
(Tables 2.13 and 2.14) by using hot start taq DNA polymerase.  
 
Table 2.13: MSP PCR mix 
Stock Conc. PCR Ing. 1X Final Conc. 
10X Hot Start Taq 
Buffer  
2.0µL 1X 
10mM dNTP Mix 0.5µL 0.4mM 
10 µM Forward Primer 1.0µL 0.2 µM 
10 µM Reverse Primer 1.0µL 0.2 µM 
100ng/µL Template DNA 1.0µL 10ng/ul 
5u/µL Hot star Taq  0.2µL 0.1u/µL 
- dH2O 14.3  
 TOTAL 20 µL  
 
Table 2.14: MSP PCR program 
Initial Denaturation 95°C 15 min  
Denaturation 95°C 30 sec  
X35 Annealing 62°C 30 sec 
Extension 72°C 30 sec 
Final Extension 72°C 10 min  
Final Hold 4°C ∞  
 
PCR products were run on 1% agarose gel using 1X TAE buffer. 
2.5.3. BISULFITE SEQUENCING (BSS) 
Bisulfite sequencing is used to determine the exact methylation pattern of the second 
exon of MEFV gene. BSS is more informative compared to MSP technique since 
BSS allow quantification of DNA methylation at each CpG site. For BSS, two 
primers are designed to amplify bisulfite treated DNA, and since the primers are 
equally specific to methylated, bisulfite treated DNA and unmethylated, bisulfite 
treated DNA amplification of these two DNAs were performed within the same 
reaction. After amplification of target region, PCR products were sequenced. 
2.5.3.1. BSS PRIMER DESIGN 
To select appropriate BSS primers, MethPrimer software was used. The software 
chooses forward and reverse primers on the regions which show least difference 
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between bisulfite treated methylated and bisulfite treated unmethylated DNAs 
(Figure 2.7). These mostly different sites are the non-CpG sites. In contrast to MSP 
primers, BSS primers are common for both bisulfite treated methylated and bisulfite 
treated unmethylated DNAs. So, BSS primer selection criteria is that they should be 
selected at non-CpG sites to amplify methylated and unmethylated DNAs together 
with a common primer pair during PCR amplification. BSS primer sequences are 
given in table 2.15. 
 
Figure 2.7: Bisulfite Sequencing Primers 
 
Table 2.15: BSS Primer sequences 
BSSF  5’- GTTTTTTGGGGGAGAATAAG -3’ 
BSSMefvR1  5’ - TTTCCAAAACCTTCCTTCAAAT -3’ 
 
2.5.3.2. BSS PCR CONDITIONS 
Since the starting amount of bisulfite treated DNA concentration was low (5ng/µl) 
two rounds of PCR was needed to amplify the target sequence. First round PCR 
amplicon was used as a template in the second round PCR. In both PCR reactions, 
hot start taq was used. The PCR mix and PCR program of first round BSS PCR is 
given in tables 2.16 and 2.17 whereas the PCR mix and PCR program of the second 
round BSS PCR is given in tables 2.18 and 2.19. 
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PCR conditions of the first round of BSS PCR is given in tables 2.16 and 2.17 
Table 2.16: PCR mix of first round BSS PCR 
Stock Conc. PCR Ing. 1X Final Conc. 
10X Hot Star Taq Buffer 5 µL 1X 
2mM dNTP Mix 4 µL 200 µM 
10 µM BSSF 1 µL 0.2 µM 
10 µM BSSMefvR1 1 µL 0.2 µM 
- Bisulfite Treated 
Genomic Dna 
2 µL - 
5u/µL Hot Star Taq 0.25 µL  
- dH2O 36.75 µL  
 TOTAL 50 µL  
 
Table 2.17: PCR program of first round PCR 
Initial Denaturation 95°C 15 min  
Denaturation 95°C 30 sec  
X35 Annealing 52°C 30 sec 
Extension 72°C 30 sec 
Final Extension 72°C 1 min  
Final Hold 4°C ∞  
 
PCR conditions of the first round of BSS PCR is given in tables 2.18 and 2.19 
Table 2.18: PCR mix of second round BSS PCR 
Stock Conc. PCR Ing. 1X Final Conc. 
10X Hot Star Taq Buffer 5 µL 1X 
2mM dNTP Mix 4 µL 200 µM 
10 µM BSSF 1 µL 0.2 µM 
10 µM BSSMefvR1 1 µL 0.2 µM 
- BSSI Amplicon 2 µL - 
5u/µL Hot Star Taq 0.25 µL  
- dH2O 36.75 µL  
 TOTAL 50 µL  
 
Table 2.19: PCR program of second round PCR 
Initial Denaturation 95°C 15min  
Denaturation 95°C 30 sec  
X35 Annealing 55°C 30 sec 
Extension 72°C 30 sec 
Final Extension 72°C 1 min  
Final Hold 4°C ∞  
 
 
PCR products were run on 1% agarose gel using 1X TAE buffer. 
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2.5.3.3. SEQUENCE PCR 
In order to obtain the nucleotide sequence of BSS PCR fragments, sequence PCR 
was done. Sequence PCR protocol is given in table 2.20 and sequence PCR program 
is given in table 2.21. 
 
Table 2.20: Sequence PCR mix 
Stock Conc. PCR Ing. 1X 
5X Sequence Buffer 2 µL 
10 µM BSSF or BSSMefvR1 1 µL 
- BSS PCR Amplicon 1 µL 
5u/µL Big Dye 2 µL 
- dH2O 4 µL 
 TOTAL 10 µL 
 
Table 2.21: Sequence PCR program 
Initial Denaturation 95°C 5 min  
Denaturation 95°C 45 sec  
X40 Annealing 50°C 45 sec 
Extension 60°C 4 min 30 sec 
Final Hold 4°C ∞  
 
2.5.3.4. PURIFICATION OF SEQUENCE PCR PRODUCTS 
Purification of sequence PCR products were performed according to the protocol 
given below: 
• 10 µl Sequence PCR amplicon was transferred into 1.5ml microcentrifuge 
tube. 
• 2 µl of 3mM NaAC was added to each tube. 
• 50 µl of 95% ethanol was added into the tubes, mixed, and remain on ice for 
30 minutes. 
• Samples are centrifuged 30 min at 14000rpm and supernatant was removed. 
• 200 µl of 70% ethanol was added into each tube and vortexed. 
• Samples are centrifuged 30 min at 14000rpm and supernatant was removed. 
• Tubes are incubated at 95ºC for 5 minutes to allow complete evaporation of 
remaining ethanol as the covers of the tubes are open. 
• 20 µlof formamide was added into the tubes and tubes are vortexed for at 
least one minute. 
• Tubes are centrifuged briefly to collect the sample at the bottom of the tube. 
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• Samples are incubated at 95ºC for 5 minutes to denaturate the secondary 
structures of amplicons. 
• Samples are immediately put on ice for 5 minutes and kept at 4ºC until 
loading to capillary gel of sequencer. 
2.5.3.5. SEQUENCE DATA ANALYSIS 
After the sequencing results are obtained, they were translated using chromas 
software. Triple alignment was done for methylated bisulfite treated DNA nucleotide 
sequence , unmethylated bisulfite treated DNA nucleotide sequence, and each sample 
sequence obtained from sequencing results to see whether the sample’s nucleotide 
sequence matches with methylated one or unmethylated one. For alignment, clustalw 
software was used. In addition to alignment, chromotogram peak hights of cytosines 
and/ or thymidines  at CpG positions are measured by using an online software called 
PixelRuler. A table was composed from this peak hight data for each of the 18 DNAs 
at more than 25 CpG dinucleotide sites. Cytosine peak hights (x) and thymidine peak 
hights were used to calculate relative cytosine (x/(x+y)) and relative thymidine 
(y/(x+y)) peak hights. For each DNA, for more than 25 CpG sites, methylation 
frequency charts were obtained. In addition, methylation differences were compared 
between wildtype samples and E148Q ones. Methylation results are also compared 
by MEFV expression levels obtained from another study of human genetics group.  
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3. RESULTS 
3.1. CpG ISLAND ANALYSIS RESULTS 
MEFV gene has a GC content of 51% at the genomic DNA level whereas this value 
is 59% at cDNA level. The second exon contain relatively more guanine and 
cytosine nucleotides and has a GC content of 66%. Since CpG islands are frequently 
found at GC-rich parts of the genome, MEFV genomic sequence was analyzed in 
terms of CpG islans (CpG Island Searcher software, USC). A 998 bp CpG island 
with a GC content of 61.2 and observed/expected CpG density of 0.653 was found 
spanning the entire second exon of MEFV gene (Figure 2.1). Within this CpG island, 
568 bp region containin 41 CpG sites within its sequence was selected for 
methylation analysis. CpG sites are given in appendix C. 
 
 
Figure 3.1: CpG island on the MEFV genomic DNA sequence 
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and tymidine (red) peaks. In the case of reverse primer-red sequences, CpG sites are 
seen as overlapping guanine (black) and adenine (green) peaks. Overlapping peaks 
indicate partial DNA methylation whereas single cytosine (in forward primer-red 
sequence, figure 3.9) or single guanine (in reverse primer-red sequence, figure 3.10) 
peaks indicate a complete (100%) methylation at that CpG site.  
 
Figure 3.9: Forward primer-red BSS sequence 
 
Figure 3.10: Reverse primer-red BSS sequence 
3.5. DNA METHYLATION AND MEFV EXPRESSION ANALYSIS 
Obtained DNA methylation patterns of the second exon of MEFV gene was 
compared to MEFV gene expression levels of individuals. Two subgroups which are 
E148Q hetrozygotes and wildtypes were also compared to eachother in terms of 
second exon methylation (Figure 3.11), and CpG methylation at E148Q site (Figure 
3.12). 
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Figure 3.11: Global methylation at the second exon of MEFV gene compared to 
MEFV gene expression levels. 
 
Figure 3.12: CpG methylation at E148Q site compared to MEFV gene expression. 
For 18 samples analyzed, a CpG pattern throughout the second exon of MEFV gene 
was obtained by using the average CpG methylation of each CpG site in all of the 
samples (wildtypes together with heterozygotes). The results are given in the figure 
3.13. 
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
15
2
16
8
15
3
15
4
15
5
15
6
15
7
15
8
15
9
16
0
16
1
16
2
16
3
16
4
16
5
16
6
16
7
M
et
hy
la
ti
on
 &
 M
EF
V
 E
xp
re
ss
io
n
Sample ID
2nd Exon Methylation
MEFV Expression
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
152168153154155156157158159160161162163164165166
M
et
hy
la
ti
on
 &
 M
EF
V
 E
xp
re
ss
io
n
Sample ID
MEFV Expression
CpG E148Q
 38 
 
 
Figure 3.13: Average CpG methylation for each CpG site throughout the second 
exon of MEFV gene. Methylation level of each CpG is the average of wildypes and 
heterozygotes together.  
 
Determination of global methylation pattern of the second exon of MEFV gene 
revealed that there is a difference between the first half of the exon and the second 
half of the exon. The comparison of average methylation of the first half of the 
second exon and average methylation of the second half of the second exon were 
compared both in wildtype and E148Q heterozygote samples. The results are shown 
in figure 3.14. 
 
Figure 3.14: Comparison of average DNA methylation between the first half and the 
second half of the second exon of MEFV gene. 
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To compare the global methylation of second exon between wildtype and E148Q 
heterozygotes, the average DNA methylation of each CpG at the second exon of 
wildtypes are compared to heterozygote ones. The data obtained from this 
comparison is given in figure 3.15. 
 
Figure 3.15: DNA Methylation comparison between wildtype and E148Q 
heterozygotes for each CpG site. 
In order to check whether second exon methylation levels have a relationship with 
MEFV expression, wildtype and heterozygote samples are compared in terms of 
average second exon methylation and average MEFV gene expression. The results 
are given in figure 3.16. 
 
Figure 3.16: Comparison of average DNA methylation of second exon of MEFV 
gene and average MEFV expression between wildtype and E148Q heterozygote 
samples. 
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To determine whether CpG methylation level of E148Q site have a relationship with 
MEFV expression, wildtype and heterozygote samples are compared in terms of 
average CpG methylation of E148Q site and average MEFV gene expression. The 
results are given in figure 3.17. 
 
Figure 3.17: Comparison of average DNA methylation of E148Q site and average 
MEFV expression between wildtype and E148Q heterozygote samples. 
In addition to comparison between E148Q heterozygotes and wildtype samples, 9 FMF 
samples were compared with 15 healthy controls which do not have FMF disease. MEFV 
expression levels of these samples were also analyzed in connection with their second exon 
methylation (Figure 3.18) and methylation of CpGs at positions 9 10 and 11 (which can be 
seen in appendix C) that is given in figure 3.19. 
 
Figure 3.18: Average MEFV Expression vs Average Exon Methylation Comparison Between 
FMF Samples (N=9) and Healthy Controls (N=15) 
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Figure 3.19: Average MEFV Expression vs Average CpG Methylation (at 9th, 10th and 11th 
Position) Comparison Between FMF Samples (N=9) and Healthy Controls (N=15) 
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4. DISCUSSION 
In this study, DNA methylation analysis was established by Methylation Specific 
PCR and direct bisulfite sequencing techniques. The target region of methylation 
analysis was the CpG island spanning the second exon of MEFV gene. 
To determine the methylation pattern of the second exon of MEFV gene, bisulfite 
treatment was performed to modify unmethylated cytosines into thymidines. The 
efficiency of bisulfite treatment is important for complete conversion of 
unmethylated cytosines into thymidines. Otherwise, some unmethylated cytosines 
remain the same and may give false positives. The control of bisulfite treated – MSP 
amplified DNA fragment showed a complete conversion for 6 unmethylated cytosine 
residues within the amplified sequence. On the other hand, according to bisulfite 
sequencing results, at non-CpG sites all of the cytosine residues are completely 
converted to thymidine residues which indicate a high yield for bisulfite conversion 
in this study. 
Positive controls of Methylation Specific PCR was also gived the expected 
amplification pattern with MSP. M primers amplified only methylated, bisulfite 
treated DNA but not unmethylated, bisulfite treated DNA; whereas U primers 
amplified only unmethylated, bisulfite treated DNA but not methylated, bisulfite 
treated DNA. Establishment of MSP with these positive control primers is essential 
in terms of the reliability of methylation analysis of DNA samples. 
MSP analysis of 18 DNA samples showed that in all of the samples, M primers 
amplified the target sequence whereas U primers not with a 35-cycle PCR reaction. 
This preliminary data showed that the second exon of MEFV gene is highly 
methylated.  
During the establishment of bisulfite sequencing technique, it was seen that the initial 
template DNA amount plays a key role on bisulfite sequencing PCR. Thus, first 
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round PCR did not amplified the target bisulfite sequencing fragment, a second 
round of PCR was needed  using the first PCR amplicon as template DNA.  
For both MSP and BSS PCR amplifications, it was seen that the hot start PCR 
technique is essential for amplification. Hot start PCR technique with Taq DNA 
Polymerase (fermentas) and classic PCR technique with HotStart Taq (Takara) were 
both worked very well, whereas no amplification was obtained in classical PCR 
technique with Taq DNA Polymerase (Fermentas). 
Bisulfite sequencing was done for each sample with a forward and with a reverse 
primer to set internal control of methylation quantification for BSS technique. In all 
of the DNA samples, reverse primers worked better than forward primers, which is a 
common case in BSS. For forward primers, 10 out of 18 sequencing results could’t 
be obtained. For the 8 samples which have two sequencing results with forward and 
with reverse primers, the methylation frequency of certain CpGs at the overlapping 
sites were compared in order to see whether there is a difference between two BSS 
results of forward and reverse primers for the same DNA fragment. The results 
showed that there is perfect match between the methylation pattern determined with 
forward primer and with reverse primers at he indicated CpG sites, which show the 
reliability of the BSS methylation quantification. 
According to the CpG methylation analysis with BSS technique, approximately 35 
CpG sites were characterized in terms of DNA methylation for each of the 18 DNA 
samples. 15 of the samples were wildtype whereas 3 of the samples were E148Q 
heterozygotes. E148Q mutation eliminates a CpG site and thus expected to decrease 
DNA methylation at mutation site.  
The results of  alignments of bisulfite sequencing data showed that when methylated 
and unmethylated control sequences are compared, 95% of the DNA samples were 
directly matched with the methylated DNA pattern which confirmed MSP results.  
A common methylation pattern was observed througout the CpG island nearly all of 
the 18 samples, where the methylation was relatively higher at 7th, 14th, 20th, 25th, 
29th, and 35th CpG positions compared to the rest of the sequence.  The 9th CpG is 
the E148Q site. A slight decrease was observed at the 9th CpG in heterozygotes. 
Average CpG methylation at the 9th CpG is 0.35 in E148Q heterozygotes whereas 
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this value is 0.55 in wildtypes. On the other hand, average CpG methylation of 
second exon was found to be the same between wildtype and heterozygote samples 
(73%) which indicate E148Q mutation does not not have any effect on global DNA 
methylation of the second exon.  
Another important data obtained from BSS methylation quantification is that, 
independent of the genotype, the second half of the exon was slightly more 
methylated than the first half. Since the first half, especially the first 3 CpGs at the 
analyzed site are more close to the 5’ UTR of the MEFV gene,  methylation amount 
of that CpGs may be lower due to positional effect relative to the promoter site. 
DNA methylation levels were also compared with the MEFV expression data. No 
relationship was found between the global methylation levels of the second exon of 
MEFV gene and MEFV expression between wildtype and E148Q heterozygote 
subgroups. However, when witldtype and E148Q hetrozygotes were compared, 
methylation amount of 9th CpG (E148Q site) was found to be strongly associated 
with MEFV expression. CpG methylation at the site of E148Q mutation was found to 
be reversely proportional with MEFV gene expression. Additionally, in nearly all of 
the samples, average DNA methylation was higher than 50% whereas this value was 
significantly lower in the first 3 CpGs. 
Moreover, DNA methylation patterns of the second exon of MEFV gene was 
compared between FMF samples and healthy controls. The exon-wide methylation 
pattern (for the second exon of MEFV gene) wasn’t found to be significantly 
different between these subgroups. However, CpGs at positions 9, 10, and 11 were 
found to have 10 to 15 percent lower methylation level when compared to healthy 
controls. CpG methylation versus MEFV experiments between these two subgroups 
did not give any correlation with MEFV expression and DNA methylation pattern of 
the second exon of MEFV gene. 
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5. CONCLUSION AND FURTHER COMMENTS 
MEFV was identified as the candidate gene of FMF disease. There are 5 common 
mutations within MEFV gene which were found to be associated with disease 
pathology. One of these mutations, E148Q was shown to increase MEFV expression, 
which causes a milder phenoype and also suggested to be preventive against 
amyloidosis. These data support that this polymorphism may be functional. 
When MEFV gene is analyzed by bioinformatic tools, a CpG island spanning the 
second exon and containing the E148Q site was found. By using DNA methylation 
analysis techniques like methylation specific PCR and Bisulfite Sequencing, 
methylation pattern of this CpG island was established during this study. It was 
found that CpG methylation is lower at the first parts of the CpG island, which is 
closer to the promoter site. The second half of the CpG island was heavily 
methylated compared to first half. 
Since E148Q mutation eliminates a CpG site within this CpG island, DNA methis 
methylation levels of wildtype and E148Q heterozygote samples were compared to 
see if there is a difference between methylation levels between thses subgroups. In 
terms of global CpG island methylation, no difference was observed, but at E148Q 
site, a slight decrease in DNA methylation was observed in E148Q heterozygotes 
comnpared to wildtype samples. The methylation data was also compared with the 
MEFV gene expression levels obtained by another study of Human Genetics Group. 
According to this analysis, MEFV gene expression was shown to reversely 
proportional with E148Q site methylation. 
In this study, 15 wildtype and 3 E148Q heterozygote samples were analyzed in terms 
of methylation of second exon of MEFV gene. As a further aspect, the number of 
samples can be increased to obtain more reliable results. Analyzing DNA 
methylation pattern of E148Q homozygote mutant samples can give additional 
information. 
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In addition, since MEFV levels were shown to be decreased in FMF patients carrying 
some MEFV mutations, DNA methylation pattern were compared between FMF 
samples and healthy controls to check whether an epigenetic regulation mechanism 
lies under the disease pathology. According to the results, no significant difference 
was found in the methylation pattern of the second exon of MEFV gene between 
FMF samples and healthy controls. At CpGs 9, 10 and 11 there will be a 10-15% 
decrease in CpG methylation and this can be further studied in terms of MEFV gene 
expression regulation. 
Finally, these in vivo methylation studies can be confirmed by in vitro cell culture 
studies which can be also useful for further methylation & gene expression 
experimets. 
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APPENDIX A 
 EQUIPMENT 
Balances    Precisa 620C SCS 
     Precisa BJ 610C 
Centrifuges    Sigma 1-13 B. Braun International 
     Allegra 25R Centrifuge Beckman Coulter 
Electrophoresis equipments E – C mini cell primo EC320 
Gel Documentation System  UVI PhotoMW Version 99.05 for Windows 
Pipettes    Gilson Pipetman 20 μL 200 μl, 1000 μl 
     Thermo Finnpipette 10 µL,  
pH meter     Mettler Toledo MP220 
Spectrophotometer   PerkinElmer Lambda25 UV/VIS Spectrometer 
Thermo cycler     Applied Biosystems GeneAmp PCR  
System 2700 
Corbett PalmCycler  
Techne FTGENE 5D 
Transilluminator   Biorad UV Transilluminator 2000 
Vortex    Herdolph Reax top 
 54 
 
APPENDIX B 
B.1. CHEMICALS 
Agarose    AppliChem 
Boric acid    Amresco 
dNTP     Fermentas 
EDTA     AppliChem 
Ethanol     Riedel-de Haën 
EtBr     Amresco 
MgCl2     Fermentas 
     Takara 
Primers    IDT DNA 
Tris Base    Amresco 
10X PCR Buffer   Fermentas 
     Takara 
B.2. ENZYMES 
AvaI     Fermantas 
Taq DNA Polymerase  Fermentas 
     Takara 
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B.3. MARKERS 
Gene RulerTM 1 kb DNA Ladder    Fermentas 
 
 
Gene RulerTM DNA Ladder Low Range  Fermentas 
 
 
 
 
 
 56 
 
B.4. BUFFERS 
TE Buffer  
Tris base     10 mM 
EDTA     1 mM 
Add ddH2O to 1 liter and adjust the pH to 8.0 
TBE (Tris-Borate-EDTA) Buffer (10X) 
Tris base    108 g  
Boric Acid    55 g 
EDTA     40 ml (0.5 M, pH 8.0) 
Add ddH2O to 1 liter and adjust the pH to 8.0 
Mini Agarose Gel (1%)  
Agarose    0.5 g 
TBE buffer (1X)   50 mL 
Add 1.5 μL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Midi Agarose Gel (1%)  
Agarose    1.5 g 
TBE buffer (1X)   150 mL 
Add 4.5 μL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
B.5. USED KITS 
DNA Isolation  8 Lx Magtration® Genomic DNA kit 
Bsiulfite Treatment              Qiagen EpiTect Bisulfite Kit  
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APPENDIX C 
CpG SITES ON BSS-ANALYZED SEQUENCE 
Methylated        GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
Unmethylated      GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                  ************************************************* ******** * 
 
Methylated        AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
Unmethylated      AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                  ******* ****** *** *** ***** *************** ************* * 
 
Methylated        AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
Unmethylated      AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                  **** ************* ******************* *************** ***** 
 
Methylated        GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
Unmethylated      GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                  ******* * ************* ***** ****** ******** *** ********** 
 
Methylated        TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
Unmethylated      TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                  * ************* ****************** ****** ***** ******* **** 
 
Methylated        GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
Unmethylated      GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                  **** * ******************** ****** **** ******************** 
 
Methylated        TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
Unmethylated      TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                  **** **************** ********** *************************** 
 
Methylated        TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
Unmethylated      TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                  *************** *** **************************************** 
 
Methylated        TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
Unmethylated      TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                  *** *********** ************* *************** ************** 
 
Methylated        TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
Unmethylated      TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
                  *** ************************ 
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APPENDIX D 
BSS ALIGNMENT FILES OF 18 SAMPLES 
(M indicate methylated bisulfite treated DNA, U indicate unmethylated, bisulfite treated 
DNA, and S indicate Sample) 
Sample 149 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 1S0 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 1S0 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               -------------------------------------------------------GGAGG 5 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                       ***** 
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT S40 
S               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 65 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT S40 
                ******* * ************* ***** ****** ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 1S5 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 185 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 4S0 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT S45 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 4S0 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 305 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGG--------------------- 344 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** ************* ********                       
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 152 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ----------GGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 50 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                          ******** ******************* *************** ***** 
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 2S0 
S               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 110 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 2S0 
                ******* * ************* ***** ****** ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 170 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAAGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 230 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ***** ************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT S20 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 290 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT S20 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG S80 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 350 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG S80 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 5S0 
S               TTGCGAATTTGGATTCGGTAATAGAATTTCGGG--------------------------- 383 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 5S0 
                *** *********** ************* ***                            
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
 
 
 
 
 
 
 
 
 
 60 
 
Sample 153 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG S0 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG S0 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ------------------------------------------------------------ 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                             
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               -------------------------------------GGTTTTGTCGGGCGGGAGAAGTT 23 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                                                     ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 83 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 3S0 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGTGTTTCGGGGTAGAAGGAGTGTAGGT 143 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 3S0 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTTGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 203 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 2S3 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATA------------------------------------- 28S 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** *******                                      
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 5S8 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 5S8 
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Sample 154 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 1S0 
S               ------------------CGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 42 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 1S0 
                                   ******************* *************** ***** 
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 102 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                ******* * ************* ***** ****** ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 162 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 222 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 2S2 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 4S0 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 342 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 4S0 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAA----------------------------------------------------- 349 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** ***                                                      
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 56S 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 56S 
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Sample 155 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               -------------GAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 47 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                             ************************************ ******** * 
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGG-AGTTGTTAGTTTGCGGTGTAGTTAGTTC 119 
S               AGGGGAATGGTTTTTGGTCGTACGGGGGCGGGAGTTGTTAGTTTGCGGTGTAGTTAGTTT S 7 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGG-AGTTGTTAGTTTGTGGTGTAGTTAGTTT 119 
                ******* ****** *** *** ***** ** ************* *************  
 
M               GAGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAG 179 
S               GAGGTCGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTATCGGAG 167 
U               GAGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAG 179 
                ***** ************* ******************* ************* * **** 
 
M               GGTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGT 239 
S               GGTTTGGATGCGTAGGGTAAGTTTTGGATTCGGAGTTCGGTTTTGTTGGGCGGGAGAAGT 227 
U               GGTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGT 239 
                ******** * ************* ***** ****** ******** *** ********* 
 
M               TTCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTT 299 
S               TTCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTT 287 
U               TTTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTT 299 
                ** ************* ****************** ****** ***** ******* *** 
 
M               AGTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGG 359 
S               AGTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGG 347 
U               AGTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGG 359 
                ***** * ******************** ****** **** ******************* 
 
M               TTTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATT 419 
S               TTTTTCGAAGTGTATTTGTTTTTGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATT 407 
U               TTTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATT 419 
                ***** **************** ********** ************************** 
 
M               TTTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATA 479 
S               TTTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATA 467 
U               TTTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATA 479 
                **************** *** *************************************** 
 
M               GTTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTA 539 
S               GTTGCGAATTTGGATTCGGTAATAGAATTTCGGG-------------------------- 501 
U               GTTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTA 539 
                **** *********** ************* ***                           
 
M               TTTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ----------------------------- 
U               TTTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 156 
 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG S 0 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG S 0 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ------------------------------------------------------------ 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                             
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               --------------------------------------------------GGGAGAAGTT 10 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                                                                  ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 70 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 130 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTCTTCTTT 190 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** ******************** ** *** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 250 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGA----------------------------------------------- 263 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********                                                
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 157 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ------------------------------------------------------------ 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                             
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               -------------------------------------GGTTTTGTCGGGCGGGAGAAGTT 23 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                                                     ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 83 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT S 3 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 203 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 263 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAATTT------------------------------- 292 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** *************                                
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 158 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ------------------------------------------------------------ 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                             
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               ---------------------------------------------CGGGCGGGAGAAGTT 15 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                                                              *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 75 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGGAGGAGTGTAGGT 135 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******* ************ 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 195 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 255 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAATTCTG----------------------------- 286 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** ************  *                              
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 159 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               -----------------------------GGAGTTGTTAGTTTGCGGTGTAGTTAGTTTG 31 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                             *************** ************* * 
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG S 0 
S               AGGTCGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 91 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG S 0 
                **** ************* ******************* *************** ***** 
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTTGGGCGGGAGAAGTT 151 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                ******* * ************* ***** ****** ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 211 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 271 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 331 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 391 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAATTTCGGG--------------------------- 424 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** ************* ***                            
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 160 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 1S  
S               ------------------------------------------------GTAGTTAGTTCG 12 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 1S  
                                                                ********** * 
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               AGGTCGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 72 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                **** ************* ******************* *************** ***** 
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 132 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                ******* * ************* ***** ****** ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 192 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 252 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 4S  
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 312 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 4S  
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 372 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAG------------------------------------ 396 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** ********                                     
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 161 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ------------------------------------------------------------ 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                             
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               --------------------------------------------------GGGAGAAGTT 10 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                                                                  ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 70 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGCGGTAGAAAGAGTGTAGGT 130 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** * ******* ********** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 190 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 250 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAAT--------------------------------- 277 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** ***********                                  
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 162 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ---------------------------------------------------------TCG 3 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                         * * 
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTCGGAGG 63 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                **** ************* ******************* *************** ***** 
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT S 0 
S               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 123 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT S 0 
                ******* * ************* ***** ****** ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCAGTTGCGTAGAAACGTTA 183 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ******  **** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAAGAGTGTAGGT S 3 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ********* ********** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 303 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 363 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAATTTC------------------------------ 393 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** *************                                
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 163 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               --------------------------------------------------------GAGG 4 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                        **** 
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 64 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                ******* * ************* ***** ****** ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TTGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 124 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 184 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 244 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 304 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAAT--------------------------------- 331 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** ***********                                  
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 164 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ------------------------------------------------------------ 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                             
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               ---------------------------------------------------GGAGAAGTT 9 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                                                                   ********* 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTTAGTTGCGTAGAAACGTTA 69 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ******  **** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAAGAAGAGTGTAGGT 129 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******  * ********** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 189 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGA------------------ 231 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **********************                   
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               ------------------------------------------------------------ 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                                                                             
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 165 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ------------------------------------------------------------ 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                             
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               -----------------------------------------------GGCGGGAGAAGTT 13 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                                                               ** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA S 0 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTTAGTTGCGTAGAAACGTTA 73 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA S 0 
                * ************* ****************** ******  **** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGGAGGAGTGTAGGT 133 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******* ************ 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTTGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 193 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 253 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAATTTCGGG--------------------------- 286 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** ************* ***                            
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 166 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ------------------------------------------------------------ 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                             
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               ------------------------------------------------------------ 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                                                                             
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               ----TTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 56 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                    *********** ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 116 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTACTATTT 176 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** ********************* ***** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 236 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAATTTC------------------------------ 266 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** *************                                
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 167 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               ------------------------------------------------------------ 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                                             
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               -----------------------------------------------GGCGGGAGAAGTT 13 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                                                               ** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 73 
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 360 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 133 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT 360 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 193 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 253 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGA----------------------------------- 278 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** *********                                    
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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Sample 168 
M               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTCGAGGGGAACG 60 
S               ------------------------------------------------------------ 
U               GTTTTTTGGGGGAGAATAAGTTTAGGAGTTTGAAGATTTTAGATTATTTTGAGGGGAATG 60 
                                                                             
 
M               AGGGGAACGGTTTTCGGTCGTACGGGGGCGGAGTTGTTAGTTTGCGGTGTAGTTAGTTCG 120 
S               ------------------------------------------------------------ 
U               AGGGGAATGGTTTTTGGTTGTATGGGGGTGGAGTTGTTAGTTTGTGGTGTAGTTAGTTTG 120 
                                                                             
 
M               AGGTCGGGAGGGGGTTGTCGAGGAAGTTTTTGAGTAAACGTAGAGAGAAGGTTTCGGAGG 180 
S               --------------------------------------------AGAAAGGTTTCGGAGG 16 
U               AGGTTGGGAGGGGGTTGTTGAGGAAGTTTTTGAGTAAATGTAGAGAGAAGGTTTTGGAGG 180 
                                                               ******* ***** 
 
M               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTCGGGCGGGAGAAGTT 240 
S               GTTTGGACGCGTAGGGTAAGTTTCGGATTCGGAGTTCGGTTTTGTTGGGCGGGAGAAGTT 76 
U               GTTTGGATGTGTAGGGTAAGTTTTGGATTTGGAGTTTGGTTTTGTTGGGTGGGAGAAGTT 240 
                ******* * ************* ***** ****** ******** *** ********** 
 
M               TCGGTTTTTGTAGGGCGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 300 
S               TCGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTCGAGGTTCGGTTGCGTAGAAACGTTA 1S  
U               TTGGTTTTTGTAGGGTGTTAGAGGGGGGTTAGGTTGAGGTTTGGTTGTGTAGAAATGTTA 300 
                * ************* ****************** ****** ***** ******* **** 
 
M               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT S 0 
S               GTTTCGCGGGGAGGTTGTAGGGGTTGGCGGGGGGCGTTTCGGGGTAGAAGGAGTGTAGGT 196 
U               GTTTTGTGGGGAGGTTGTAGGGGTTGGTGGGGGGTGTTTTGGGGTAGAAGGAGTGTAGGT S 0 
                **** * ******************** ****** **** ******************** 
 
M               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGCGATTTAGAAGTTTTGAGGTTATTATTT 420 
S               TTTTCGAAGTGTATTTGTTTTCGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 256 
U               TTTTTGAAGTGTATTTGTTTTTGGGAAAGATGTGATTTAGAAGTTTTGAGGTTATTATTT 420 
                **** **************** ********** *************************** 
 
M               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
S               TTATAGGGGAGAAGGCGTTCGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 316 
U               TTATAGGGGAGAAGGTGTTTGTAAATTTAGAAATTTTTTTGATTTTAGAGGAAAAGATAG 480 
                *************** *** **************************************** 
 
M               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTAAGGTTTATTTCGGATGGAGGGGTAT 540 
S               TTGCGAATTTGGATTCGGTAATAGAATTTCGGGTA------------------------- 351 
U               TTGTGAATTTGGATTTGGTAATAGAATTTTGGGTAAGGTTTATTTTGGATGGAGGGGTAT 540 
                *** *********** ************* *****                          
 
M               TTGCGGATTTGAAGGAAGGTTTTGGAAA 568 
S               ---------------------------- 
U               TTGTGGATTTGAAGGAAGGTTTTGGAAA 568 
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APPENDIX E 
CpG METHYLATION MAPS OF 18 SAMPLES 
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